Search Results
Nov 12, 2025, 16:00 ET Fractal Wins Microsoft Partner of The Year 2025
Qure.ai, a global healthcare AI leader enhancing the rapid identification and management of tuberculosis, lung cancer, and stroke. Fractal's dedicated AI research team is focused on foundational AI advancements, including knowledge-based foundational models,
More news about: Fractal Analytics Limited
Nov 12, 2025, 09:00 ET AtomVie Global Radiopharma Supplies the First Patient Dose of 225Ac-SSO110 for Ariceum Therapeutics' Phase 1/2 SANTANA-225 Clinical Trial in Extensive-Stage Small Cell Lung Cancer and Merkel Cell Carcinoma
somatostatin type 2 receptor (SSTR2), being evaluated in Ariceum's Phase 1/2 clinical trial (SANTANA-225) for the treatment of extensive-stage small cell lung cancer (SCLC) and Merkel Cell Carcinoma (MCC).
More news about: AtomVie Global Radiopharma Inc.
Nov 12, 2025, 09:00 ET AtomVie Global Radiopharma Supplies the First Patient Dose of 225Ac-SSO110 for Ariceum Therapeutics' Phase 1/2 SANTANA-225 Clinical Trial in Extensive-Stage Small Cell Lung Cancer and Merkel Cell Carcinoma
somatostatin type 2 receptor (SSTR2), being evaluated in Ariceum's Phase 1/2 clinical trial (SANTANA-225) for the treatment of extensive-stage small cell lung cancer (SCLC) and Merkel Cell Carcinoma (MCC).
More news about: AtomVie Global Radiopharma Inc.
Nov 12, 2025, 09:00 ET New Study in Sub-Saharan Africa Demonstrates Specialist-Level Heart Failure Detection Using Eko's AI-Enabled Stethoscope
HealthEko Health is a pioneering AI early disease detection company advancing how healthcare professionals detect and monitor heart and lung disease through its portfolio of digital stethoscopes, ECG devices, software, and AI-powered analysis. Its FDA-cleared platform, with more than 650,000
More news about: Eko Health
Nov 12, 2025, 09:00 ET Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Nov 12, 2025, 09:00 ET L'Oréal USA Announces 2025 For Women in Science Awardees, Underscoring Commitment to Advancing Careers in STEM
University, School of Medicine, utilizes 3D bioprinting technology to model and gain a deeper understanding of pulmonary arterial hypertension, a severe lung disease. Her work focuses on creating patient-specific models that accurately reflect the individual differences in pulmonary vascular disease. This
More news about: L'Oreal USA
Nov 12, 2025, 08:43 ET Fall Allergies, Winter Viruses, and Everyday Wellness: Why Air Quality Can't Be Ignored Now More Than Ever
"Numerous studies have established a strong connection between elevated indoor air pollution and the development of airway diseases, deterioration of lung function, the emergence of respiratory symptoms, and the exacerbation of preexisting airway conditions," Dr. Dhau added. "Air health really is daily
More news about: Molekule
Nov 12, 2025, 08:30 ET IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025
cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure.
More news about: IceCure Medical
Nov 12, 2025, 08:00 ET Wellcare Announces 2026 Annual Enrollment Period in Florida: Choose the Right Medicare Coverage That Works for You
must have one or more of the following chronic conditions: cancer, cardiovascular disorders, chronic and disabling mental health conditions, chronic lung disorders, diabetes. There are other eligible conditions not listed. Eligibility for this benefit cannot be guaranteed based solely on your condition.
More news about: Wellcare
Nov 12, 2025, 07:01 ET CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
significantly reduced Th17 cells in both the kidney and lung, significantly increased glomerular filtration rate (GFR), and decreased renal injury in a rat model of AKI. The findings, particularly the new observations of IL-17 reductions in the lung, provide strong mechanistic support for Auxora as a potential
More news about: CalciMedica, Inc.
Nov 12, 2025, 05:04 ET American Lung Association Launches Free Education and Support Program for Families Facing Rare Lung Disease
About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
Nov 11, 2025, 12:30 ET Interventional Oncology Market to Reach $4.38 Billion by 2030 at CAGR 8.55% - Grand View Research, Inc.
(Revenue, USD Million, 2018 - 2030) Liver Cancer Lung Cancer Kidney Cancer Prostate Cancer Breast Cancer
More news about: Grand View Research, Inc
Nov 11, 2025, 11:11 ET Tony Award Winner Julie Halston to Host 16th Annual Broadway Belts for PFF! 2026, Featuring America's Got Talent Star Daniel Emmet
artists, patients, caregivers, and supporters to fund research, programs, advocacy, and education for those living with pulmonary fibrosis and interstitial lung disease (ILD). Daniel Emmet is a leading voice in classical-pop crossover. A top 10 finalist on America's Got Talent (2018),
More news about: The Pulmonary Fibrosis Foundation
Nov 11, 2025, 10:13 ET Olympus Corporation Announces Newest Appointments to Help Drive Innovation and Patient Safety for Respiratory Business
respiratory failure. At Olympus, he leads the global clinical evidence strategy for respiratory devices, including bronchoscopic lung volume reduction, endobronchial valve therapy and reach-enhanced endobronchial ultrasound (EBUS) solutions. Active in pulmonary
More news about: Olympus Corporation of the Americas
Nov 11, 2025, 09:31 ET Lung Cancer Research Foundation Welcomes New Member of Board of Directors
with the potential to extend survival and improve quality of life for people with lung cancer. LCRF's mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer. To date, LCRF has funded 431 research grants, totaling nearly $49 million,
More news about: Lung Cancer Research Foundation
Nov 11, 2025, 08:58 ET iLeukon Therapeutics Presents Phase I Data for ILKN421H at SITC 2025
HSA–IL-2 variant (IL-2v), as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including first-line non-small cell lung cancer (NSCLC). The presentation highlighted ILKN421H's unique scientific design and distinct pharmacologic advantages that enable potent immune activation
More news about: iLeukon Therapeutics
Nov 11, 2025, 08:00 ET Coreline Soft Selected as Exclusive AI Provider for France's National Lung Cancer Screening Pilot Project, IMPULSION
initiative. The sessions will center on lung cancer screening and nodule management, with AI-based advanced detection tools to enhance clinical practice. The project embraces the opportunity to explore the optimal conditions that could potentially expand into a national lung cancer screening program, with AVIEW
More news about: Coreline Soft
Nov 11, 2025, 07:00 ET New Study Shows Aliya® Pulsed Electric Field Ablation Achieved Local Control of Lung Tumors in Metastatic Cancer Patients and May Induce an Immune Response
Six-month results from U.S. clinical study show promise for the innovative technology in patients with stage IV non-small cell lung cancer or lung metastasis REDWOOD CITY, Calif., Nov.
More news about: Galvanize Therapeutics, Inc.
Nov 11, 2025, 07:00 ET CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London
blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the
More news about: Cytosorbents Corp
Nov 11, 2025, 03:02 ET aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR
that, "aTyr Pharma said on Monday its experimental drug had failed to meet the main goal in a late-stage study testing it in patients with a type of lung disease known as pulmonary sarcoidosis, which impacts the lungs and lymph nodes." Based on this news, shares of aTyr traded down by more than 81% in
More news about: DJS Law Group LLP
Nov 11, 2025, 02:34 ET Guo Guangchang: Fosun Strengthens Globalization Capabilities, Accelerates Innovation through Open Cooperation
breakthroughs in the field of innovative drugs. As the world's first anti-PD-1 monoclonal antibody approved for the first-line treatment of small cell lung cancer (SCLC), HANSIZHUANG, independently developed by Henlius, has been approved for marketing in nearly 40 countries and regions, including China,
More news about: Fosun
Nov 10, 2025, 17:33 ET Wellcare Enhances Offering of Affordable, Quality Medicare Advantage and Medicare Prescription Drug Plans in 2026
must have one or more of the following chronic conditions: cancer, cardiovascular disorders, chronic and disabling mental health conditions, chronic lung disorders, diabetes. There are other eligible conditions not listed. Eligibility for this benefit cannot be guaranteed based solely on your condition.
More news about: Absolute Total Care
Nov 10, 2025, 14:40 ET INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm
October 22, 2025, Arcturus reported Phase 2 trial results for its inhaled mRNA therapy ARCT-032 in cystic fibrosis, showing no meaningful improvement in lung function (FEV1). Following the announcement, the company's stock dropped 50.17% to close at $11.54 per share.
More news about: Edelson Lechtzin LLP
Nov 10, 2025, 10:38 ET Verismo Therapeutics Presents Promising Preclinical Data at SITC 2025 for SynKIR™-110 in Solid Tumors
Activity: SynKIR™-110 cells were selectively enriched in tumors and reduced in, normal tissues – contrasting with the off-tumor accumulation in lung and normal tissues observed with conventional 41BB-CD3ζ CAR T designs. "Conventional
More news about: Verismo Therapeutics
Nov 10, 2025, 10:30 ET Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.